Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00094991
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Type 2 diabetes;
- Serum triglyceride concentration < or = 600 mg/dL;
- Body mass index < or = 37 kg/m2
Exclusion Criteria
- Type 1 diabetes;
- History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
- Congestive heart failure (NYHA Class III and IV);
- Uncontrolled hypertension;
- Women of Child Bearing Potential
- History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Local Institution
🇮🇹Pisa, Italy